Background: Emergency department (ED) patients with nonfatal opioid overdose are at high risk for subsequent fatal overdose, yet ED programs aimed at reducing harm from opioid use remain underdeveloped.
Objectives: The objective was to pilot a statewide ED take-home naloxone program and improve the care of patients with opioid use disorder (OUD) and risky drug use through training and interprofessional network building.
Methods: Nine hospital EDs with pharmacy, nurse, and physician champions were recruited, surveyed, and trained. Take-home naloxone rescue kits were developed, disseminated, and tracked. Two overdose prevention summits were convened prior to the COVID pandemic, and two X-waiver training courses aimed at emergency physicians and advanced practice providers were arranged, both in person and virtual.
Results: A total of 872 naloxone rescue kits were distributed to ED patients at risk of opioid overdose during the first phase of this project, and more than 140 providers were trained in the use of medications for OUD in acute care settings.
Conclusions: A statewide ED take-home naloxone program was shown to be feasible across a range of different hospitals with varying maturity in preexisting OUD resources and capabilities. Future work will be aimed at both expanding and measuring the effectiveness of this work.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/acem.14435 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Would provision of Take Home Naloxone Kits by Emergency Medical Services be perceived as acceptable to people at risk of opioid overdose? A qualitative study.
Prehosp Emerg Care
December 2024
Health Service Research, Swansea University Medical School.
Objectives: Take home naloxone kits can reduce mortality, but we know little about how they are perceived by people with lived experience of opioid use. Provision of naloxone in the community has been shown to significantly reduce mortality from opioid overdose. Currently, this is predominantly through drug treatment support services but expanding provision through other services might be effective in increasing kit take-up and mortality reduction.
View Article and Find Full Text PDFTake-Home Naloxone, Release From Jail, and Opioid Overdose-A Piece of the Puzzle.
JAMA Netw Open
December 2024
SEICHE Center for Health and Justice, Yale School of Medicine, New Haven, Connecticut.
Agent-Based Model of Combined Community- and Jail-Based Take-Home Naloxone Distribution.
JAMA Netw Open
December 2024
Decision and Infrastructure Sciences Division, Argonne National Laboratory, Lemont, Illinois.
Importance: Opioid-related overdose accounts for almost 80 000 deaths annually across the US. People who use drugs leaving jails are at particularly high risk for opioid-related overdose and may benefit from take-home naloxone (THN) distribution.
Objective: To estimate the population impact of THN distribution at jail release to reverse opioid-related overdose among people with opioid use disorders.
Comparative Effectiveness of Buprenorphine/Naloxone and Methadone on Methamphetamine/Amphetamine Use Among People with Opioid Use Disorder in Canada.
Subst Use Addctn J
November 2024
British Columbia Centre on Substance Use, Vancouver, BC, Canada.
Article Synopsis
- The study investigates the impact of opioid agonist therapy (OAT) on methamphetamine and amphetamine use among individuals with opioid use disorder (OUD) in Canada, comparing buprenorphine/naloxone and methadone.
- Conducted over 24 weeks, data from a pan-Canadian trial highlighted that both treatments showed no significant effect on reducing methamphetamine/amphetamine use, as assessed through drug testing and self-reporting.
- Despite methamphetamine/amphetamine use being prevalent among participants, results indicated that neither treatment method led to notable changes in their usage patterns throughout the study period.
Take-home naloxone in multicentre emergency settings: the TIME feasibility cluster RCT.
Health Technol Assess
October 2024
Department of Medicine, Swansea University, Swansea, UK.
Background: Opioids kill more people than any other drug. Naloxone is an opioid antagonist which can be distributed in take-home 'kits' for peer administration (take-home naloxone).
Aim: To determine the feasibility of carrying out a definitive randomised controlled trial of take-home naloxone in emergency settings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!